What microdosing means in this context Microdosing for GLP-1 agents typically refers to doses significantly below the weight loss threshold
The Wittmer Rejuvenation Clinic Peptide Calculator is designed to make peptide dosing straightforward and accessible for everyone
Key Takeaways Cagrilintide is a long-acting amylin analogue with clinical trial doses ranging from 0.3 mg to 4.5 mg weekly, while retatrutide is a triple agonist studied at 4 mg, 8 mg, and 12 mg weekly doses No published clinical trials currently exist evaluating the cagrilintide dosage with retatrutide combination, making any combined use experimental and off-label Both peptides work through different mechanismscagrilintide activates amylin receptors while retatrutide targets GIP, GLP-1, and glucagon receptorssuggesting potential complementary effects Gastrointestinal side effects (nausea, vomiting) occur in 60-80% of participants at higher doses for both compounds, raising concerns about additive effects when combined Proper dose escalation protocols spanning 8-20 weeks are critical for tolerability and adherence in peptide-based metabolic therapies Understanding Cagrilintide: Mechanism and Dosage Fundamentals What Is Cagrilintide
Subsequently, whole exome sequencing (WES) of simplex families with one affected child demonstrated strong association of rare de novo exonic single nucleotide variants (SNV) with ASD [20,21,22,23,24], with more recent analyses highlighting around a hundred genome-wide significant ASD risk genes [25, 26]
